Testicular cancer in Hispanics: incidence of subtypes over time according to neighborhood sociodemographic factors in California.


Journal

Cancer causes & control : CCC
ISSN: 1573-7225
Titre abrégé: Cancer Causes Control
Pays: Netherlands
ID NLM: 9100846

Informations de publication

Date de publication:
Aug 2020
Historique:
received: 25 09 2019
accepted: 04 05 2020
pubmed: 23 5 2020
medline: 1 9 2020
entrez: 23 5 2020
Statut: ppublish

Résumé

Hispanic men in the USA experience the second-highest incidence rate of testicular germ cell tumors (TGCTs), behind non-Hispanic (NH) White men, and have experienced steep increases in TGCT in recent decades. It is unknown whether increases in incidence differ according to neighborhood sociodemographic factors. We conducted a population-based study of n = 3759 Hispanic and n = 8469 NH White men (n = 12,228 total) diagnosed with TGCT in California during the three most recent pericensal periods. We calculated incidence rates according to neighborhood socioeconomic status (nSES) and among Hispanics, according to ethnic enclave. We calculated incidence rate ratios to compare rates across nSES and ethnic enclave and to examine changes in rates over pericensal time periods according to these neighborhood factors for major histologic types (i.e., seminoma and nonseminoma). Hispanic men residing in high SES, compared to low SES, neighborhoods had greater incidence of seminoma and nonseminoma testicular cancer across pericensal periods, as did Hispanic men in low enclave (less ethnic), compared to high enclave, neighborhoods. Between the periods 1998-2002 and 2008-2012, Hispanic men residing in low SES neighborhoods experienced a 39% increased incidence of seminoma, while those residing in low and middle SES neighborhoods experienced 87% and 48% increased incidence of nonseminoma, respectively. While TGCT incidence has increased among all Hispanic men, incidence increases appear to be driven disproportionately by those residing in lower SES and lower enclave neighborhoods, particularly for nonseminoma.

Identifiants

pubmed: 32440828
doi: 10.1007/s10552-020-01311-2
pii: 10.1007/s10552-020-01311-2
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

713-721

Subventions

Organisme : NCI NIH HHS
ID : HHSN261201800032I
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201800032I
Pays : United States

Auteurs

Mindy C DeRouen (MC)

Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA. mderouen@psg.ucsf.edu.
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA. mderouen@psg.ucsf.edu.
, 2nd Floor, 550 16th St, Stanford, CA, 94158, USA. mderouen@psg.ucsf.edu.

Meg McKinley (M)

Greater Bay Area Cancer Registry, San Francisco, CA, USA.

Sumit Anil Shah (SA)

Division of Oncology, Department of Medicine, Stanford School of Medicine, Stanford, CA, USA.
Stanford Cancer Institute, Stanford, CA, USA.

Hala T Borno (HT)

UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Division of Hematology/Oncology, Department of Medicine, School of Medicine, University of California San Francisco, San Francisco, CA, USA.

Rhonda Aoki (R)

Department of Health Research and Policy, Stanford School of Medicine, Stanford, CA, USA.

Daphne Y Lichtensztajn (DY)

Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
Greater Bay Area Cancer Registry, San Francisco, CA, USA.

John T Leppert (JT)

Stanford Cancer Institute, Stanford, CA, USA.
Division of Urology, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Department of Urology, Stanford School of Medicine, Stanford, CA, USA.

James D Brooks (JD)

Stanford Cancer Institute, Stanford, CA, USA.
Department of Urology, Stanford School of Medicine, Stanford, CA, USA.

Benjamin I Chung (BI)

Stanford Cancer Institute, Stanford, CA, USA.
Department of Urology, Stanford School of Medicine, Stanford, CA, USA.

Scarlett Lin Gomez (SL)

Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Greater Bay Area Cancer Registry, San Francisco, CA, USA.

Iona Cheng (I)

Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA, USA.
UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.
Greater Bay Area Cancer Registry, San Francisco, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH